Pharmaceutical Executive

Pharmaceutical Executive Daily: FDA Approves Breztri

28 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move to acquire Japanese OTC m...

Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia

27 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, adding a fi...

Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie

24 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves ...

Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent

23 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixe...

The Ron Lanton Report: Where Innovations Happens

23 Apr 2026

Contributed by Lukas

In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructu...

Pharmaceutical Executive Daily: Idvynso Receives FDA Approval

22 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weigh...

Pharmaceutical Executive Daily: UnitedHealth Raises Full-Year Profit Forecast

21 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected first-quarter results,...

Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

20 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues ...

Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning

17 Apr 2026

Contributed by Lukas

In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management...

Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo

16 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approv...

Pharmaceutical Executive Daily: Obsidian and Galera Therapeutics Enter Merger Agreement

15 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, platform innovation continues to drive biotech investment across oncology and immunology, Obsidian Therap...

Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement

14 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical in a deal worth up to $745...

Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment

13 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced melanoma, Regeneron and Te...

Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer

10 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large st...

Why Branding is Pharma’s Most Undervalued Asset

10 Apr 2026

Contributed by Lukas

In this episode of Leading Edge With Ken Banta, The Vanguard Network founder and CEO is joined by branding strategist Andy Milligan, founding partner...

Pharmaceutical Executive Daily: Shionogi Receives a Contract Through BARDA's Project BioShield

09 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant b...

Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees

08 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ahead of the company's annual...

Pharmaceutical Executive Daily: Wegovy HD Now Available in the U.S.

07 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibo...

Pharmaceutical Executive Daily: Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics

06 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Neurocrine Biosciences agrees to acquire Soleno Therapeutics for $2.9 billion to gain Vykat XR, the first a...

Pharmaceutical Executive Daily: President Trump Imposes 100% Tariff for Branded Pharmaceuticals

03 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported patented pharmaceuticals under S...

Pharmaceutical Executive Daily: Leadership Turnover Under Trump Administration

02 Apr 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump administration, Shionogi...

Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul

01 Apr 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK Jr.'s vaccine policy overhaul...

Pharmaceutical Executive Daily: Novo Nordisk's Wegovy Subscription Program

31 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy targeting cash-paying patients ...

Pharmaceutical Executive Daily: Eli Lilly Presses U.K. Government to Raise NHS Drug Pricing

30 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Eli Lilly presses the U.K. government to overhaul its NHS drug pricing framework as a condition of resuming...

Pharmaceutical Executive Daily: Novartis Acquires Excellergy Inc.

27 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire Excellergy for up to $2 billion to advance a next-generation anti-IgE therapy wh...

Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director

26 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the Trump administration misses a statutory deadline to nominate a permanent CDC director, leaving the agen...

Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

25 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims about its bladder cancer ...

Pharmaceutical Executive Daily: Bayer Shares Drop After Inclusive Capital Offloads Remaining Stake

24 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, ...

Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer

23 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase ...

Pharmaceutical Executive Daily: FDA Approves Wegovy HD

20 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth u...

The Ron Lanton Report: When Policy Becomes a Capital Event

20 Mar 2026

Contributed by Lukas

The episode explores how regulatory signals across drug approvals, trade policy, AI governance, and drug pricing shape business strategy and investor ...

Pharmaceutical Executive Daily: Analysis on TrumpRx List Pricing

19 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than w...

Pharmaceutical Executive Daily: Federal Judge Halts Vaccine Advisory Council Appointments

18 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, a federal judge blocks RFK Jr.'s reconstituted vaccine advisory committee and halts its policy changes, a n...

Pharmaceutical Executive Daily: Conflict in Middle East Disrupts Pharma Supply Chains

16 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl T...

Pharmaceutical Executive Daily: FDA Expands Approval for Arexvy

13 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses t...

Pharmaceutical Executive Daily: Senate Democrats Seeking Information on MFN Pharma Deals

12 Mar 2026

Contributed by Lukas

Moving CAR-T Beyond Oncology

11 Mar 2026

Contributed by Lukas

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

Pharmaceutical Executive Daily: FDA's New Guidance for Biosimilar Development

11 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA issues new draft guidance aimed at reducing the cost and complexity of biosimilar development, Novo...

Pharmaceutical Executive Daily: FDA Expands Approval of Leucovorin

10 Mar 2026

Contributed by Lukas

In today's Pharmaceutical Executive Daily, the FDA approves leucovorin as the first-ever treatment for an ultra-rare genetic condition called cerebral...

Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time

09 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under ...

Pharmaceutical Executive Daily: Cognito Therapeutics and Nexcure Secure Financing Rounds

05 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intel...

Pharmaceutical Executive Daily: Pharma Industry's AI Adoption

04 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Antengene and UCB enter a billion-dollar global licensing agreement for a bispecific T-cell engager, Teva...

The Ongoing Impact of MFN Pricing

04 Mar 2026

Contributed by Lukas

Alice Valdur Curan discusses how the industry continues to strategize around this complicated order.

Pharmaceutical Executive Daily: Novo Nordisk Commits $506 Million to Ireland Manufacturing Site

03 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, industry leaders examine how to measure AI’s return on investment across the life sciences value chain,...

Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya

02 Mar 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older, Sogroya becomes the f...

Pharmaceutical Executive Daily: FDA Approves Hernexeos

27 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry leaders explore the expans...

Pharmaceutical Executive Daily: Alkermes' CEO Succession Plan

26 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership c...

The Ron Lanton Report: Is Healthcare Consolidation Reaching Its Limits?

26 Feb 2026

Contributed by Lukas

The episode will explore structural implications for supply chains, distribution models, and international strategy, not a political discussion, but a...

Pharmaceutical Executive Daily: FDA Approves Braftovi

25 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves Braftovi for mutant metastatic colorectal cancer, Novo Nordisk and GSK announce major de...

Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products

24 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter...

Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna

20 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, BioNTech files a patent infringement lawsuit against Moderna, the Supreme Court rules against a large num...

Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals

19 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims & Hers enters a $1 bill...

Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine

18 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly ...

Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro

17 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary Robert F. Kennedy Jr. revi...

Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin

16 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, Edwards Lifesciences l...

Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron

13 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics with...

Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna

11 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secu...

Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales

10 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisor...

Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech

10 Feb 2026

Contributed by Lukas

In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effe...

Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill

09 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, ne...

Pharmaceutical Executive Daily: The Launch of TrumpRx

06 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerge...

Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction

05 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be trea...

Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026

04 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can ...

Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

03 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous ind...

Pharmaceutical Executive Daily: FDA Reveals PreCheck Pilot Program

02 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an A...

Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements

30 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS re...

Pharmaceutical Executive Daily: The Disconnect Between Pharma and MedTech

29 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly ...

Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics

28 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardi...

Pharmaceutical Executive Daily: Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist

27 Jan 2026

Contributed by Lukas

In today’s pharmaceutical executive daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, procurement leaders reasse...

Pharmaceutical Executive Daily: Mirum Pharmaceuticals Acquires Bluejay Therapeutics

26 Jan 2026

Contributed by Lukas

In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry ex...

Pharmaceutical Executive Daily: Tariff Uncertainty Accelerates Manufacturing Shifts

23 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing activity, workforce burnou...

Pharmaceutical Executive Daily: United States' Set to Exit WHO

22 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the World Health Organization finalizes the United States’ withdrawal from the global health body, Bris...

Pharmaceutical Executive Daily: New Study Finds No Evidence Linking Tylenol Use to Autism Risk

21 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, a new study reignites debate over a potential link between Tylenol use and autism risk, TopGum signs a $1...

Pharmaceutical Executive Daily: GSK's $2 Billion Acquisition of RAPT Therapeutics

20 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics, Atkin...

Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma

19 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class a...

Pharmaceutical Executive Daily: President Trump's Great Healthcare Plan

16 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Johnson & Johnson announces plans for a second $2 billion manufacturing facility in North Carolina, Presi...

Pharmaceutical Executive Daily: Continued Coverage of the 2026 J.P. Morgan Healthcare Conference

15 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Genmab outlining a disciplined st...

Pharmaceutical Executive Daily: 2026 J.P. Morgan Healthcare Conference Coverage

14 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen outlining how a more focus...

Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment

12 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S...

Pharmaceutical Executive Daily: FDA Limits Regulations of Non-Medical Fitness Devices

08 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry leaders examine how humans a...

Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million

07 Jan 2026

Contributed by Lukas

Pharmaceutical Executive Daily: Alnylam Invests $250 Million in Manufacturing Facility

06 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Thera...

Pharmaceutical Executive Daily: Wegovy Pill Becomes Available

05 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, clears a new therapy to pre...

Pharmaceutical Executive Daily: FDA Approves Wegovy Pill

23 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Ve...

Pharmaceutical Executive Daily: Nine New Additions to TrumpRx

22 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 b...

Scaling Sustainability: A Big Pharma Formula

22 Dec 2025

Contributed by Lukas

In this enlightening conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance (...

Pharmaceutical Executive Daily: US Senate Passes Biosecure Act

19 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. S...

Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release

18 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a ...

Pharmaceutical Executive Daily: FDA's Approval of Lerochol

17 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals spanning Alzheimer’s ...

Pharmaceutical Executive Daily: TrumpRx's Critical Blind Spot

16 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher ...

Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results

15 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna l...

Pharmaceutical Executive Daily: FDA's Approval of Waskyra

11 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for...

Pharmaceutical Executive Daily: FDA's New Standard for CAR-T Approvals

10 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA introduces a new superiority standard for future CAR-T approvals, Relation Therapeutics and Novar...

Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions

09 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data ...

Pharmaceutical Executive Daily: FDA Approves Breyanzi

08 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met its primary endpoint in a...

Pharmaceutical Executive Daily: Mark Cuban's Push for Generic Drug Fee Waivers

05 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, former FDA commissioners caution that new vaccine policies could weaken long-established regulatory stand...

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

04 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA appoints Tracy Beth Høeg as acting CDER director, health systems explore new commercialization ...

Pharmaceutical Executive Daily: FDA's Agentic AI Deployment

03 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Regeneron launches a $150 million gene editing collaboration with Tessera Therapeutics, the FDA begins ag...

Pharmaceutical Executive Daily: Lilly Reduces the Price of Zepbound

02 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly reduces the price of Zepbound single-dose vials for self-pay patients, a new report claims the ...

Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products

01 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Novo Nordisk files for FDA approval of a higher-dose Wegovy injectable using a priority review voucher, t...